Research Publications

Lack of cardioprotective effect of naproxen.

Mukherjee D, Nissen SE, Topol EJ

Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality.

Brener SJ, Lytle BW, Schneider JP, Ellis SG, Topol EJ

Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximab.

Mukherjee D, Gurm H, Tang WH, Roffi M, Wolski K, Moliterno DJ, Guetta V, Ardissinio D, Bode C, Steg G, Lincoff AM, Topol EJ

Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).

Mukherjee D, Mahaffey KW, Moliterno DJ, Harrington RA, Yadav JS, Pieper KS, Gallup D, Dyke C, Roe MT, Berdan L, Lauer MS, Mänttäri M, White HD, Califf RM, Topol EJ

Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials.

Blankenship JC, Balog C, Sapp SK, Califf RM, Lincoff AM, Tcheng JE, Topol EJ

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.

Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ, CREDO Investigators. Clopidogrel for the Reduction of Events During Observation

Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.

Lincoff AM, Califf RM, Van de Werf F, Willerson JT, White HD, Armstrong PW, Guetta V, Gibler WB, Hochman JS, Bode C, Vahanian A, Steg PG, Ardissino D, Savonitto S, Bar F, Sadowski Z, Betriu A, Booth JE, Wolski K, Waller M, Topol EJ, Global Use of Strategies To Open Coronary Arteries Investigators (GUSTO)

Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT).

Islam MA, Blankenship JC, Balog C, Iliadis EA, Lincoff AM, Tcheng JE, Califf RM, Topol EJ, EPISTENT Investigators

Economics and quality of care for patients with acute coronary syndromes: the impending crisis.

Topol EJ

The arterial inflammation hypothesis.

Bhatt DL, Topol EJ